Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Condition(s):Non-GCB/ABC Diffuse Large B-Cell Lymphoma; With and Without MyD88 and/or CD79B MutationsLast Updated:April 4, 2023Terminated
Hide Studies Not Open or Pending
Condition(s):Non-GCB/ABC Diffuse Large B-Cell Lymphoma; With and Without MyD88 and/or CD79B MutationsLast Updated:April 4, 2023Terminated
Condition(s):Non-Small Cell Lung Cancer; Squamous Non-small-cell Lung Cancer; Squamous Non-Small Cell Neoplasm of Lung; NFE2L2 Gene MutationLast Updated:April 4, 2023Terminated
Condition(s):Non-Small Cell Lung Cancer; Non-squamous Non-small-cell Lung Cancer; Non-Squamous Non-Small Cell Neoplasm of Lung; KEAP1 Gene Mutation; NRF2 Mutation; NFE2L2 Gene MutationLast Updated:March 13, 2023Terminated
Condition(s):Cardiac SafetyLast Updated:March 9, 2021Completed
Condition(s):Drug InteractionLast Updated:March 9, 2021Completed
Condition(s):Cystic FibrosisLast Updated:April 13, 2022Completed
Condition(s):Non-Small Cell Lung Cancer; Non-squamous Non-small-cell Lung Cancer; Non-Squamous Non-Small Cell Neoplasm of Lung; KEAP1 Gene Mutation; NRF2 Gene Mutation; NFE2L2 Gene MutationLast Updated:September 21, 2022Terminated
Condition(s):Solid Tumors; NSCLC; CRC; KRAS Gene MutationLast Updated:September 19, 2022Completed
Condition(s):Solid Tumor; Clear Cell Renal Cell Carcinoma; TNBC – Triple-Negative Breast Cancer; Colorectal Cancer; CRC; RCC; ccRCCLast Updated:February 17, 2022Terminated
Condition(s):Lymphoma, Non-HodgkinLast Updated:February 8, 2023Withdrawn
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.